赛托生物
(300583)
| 流通市值：46.00亿 | | | 总市值：46.88亿 |
| 流通股本：1.86亿 | | | 总股本：1.90亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 765,034,045.74 | 566,649,563.44 | 244,395,524.04 | 1,279,783,092.49 |
| 营业收入 | 765,034,045.74 | 566,649,563.44 | 244,395,524.04 | 1,279,783,092.49 |
| 二、营业总成本 | 744,755,228.96 | 553,897,255.29 | 238,473,780.69 | 1,244,249,092.87 |
| 营业成本 | 563,185,270.27 | 420,394,977.21 | 174,821,291.66 | 994,242,629.97 |
| 税金及附加 | 10,736,643.67 | 7,714,678.3 | 3,061,577.19 | 13,767,928.33 |
| 销售费用 | 12,355,834.63 | 9,182,050.56 | 4,162,068.72 | 15,666,356.24 |
| 管理费用 | 92,297,375.3 | 67,477,447.04 | 31,757,483.5 | 128,235,023.09 |
| 研发费用 | 41,391,541 | 31,496,849.65 | 14,321,901.84 | 55,076,380.87 |
| 财务费用 | 24,788,564.09 | 17,631,252.53 | 10,349,457.78 | 37,260,774.37 |
| 其中:利息费用 | 22,889,820.17 | 16,662,983.69 | 10,368,492.38 | 37,658,706.07 |
| 其中:利息收入 | 3,412,192.84 | 2,243,519.84 | 1,159,909.07 | 4,736,527.78 |
| 加:投资收益 | 10,869,510.28 | 9,671,230.51 | 1,787,943.81 | 3,611,814.66 |
| 资产处置收益 | -285,934.89 | -285,934.89 | - | 138,867.19 |
| 资产减值损失(新) | -21,710,361.39 | -6,926,755.13 | -2,244,799.22 | -13,167,357.38 |
| 信用减值损失(新) | 2,327,445.5 | -2,060,995.31 | -581,690.84 | -5,352,684.74 |
| 其他收益 | 9,702,493.42 | 6,224,900.44 | 3,198,873.33 | 11,974,160.07 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 21,181,969.7 | 19,374,753.77 | 8,082,070.43 | 32,738,799.42 |
| 加:营业外收入 | 126,774.48 | 112,633.98 | 100.09 | 25,031,289.2 |
| 减:营业外支出 | 574,653.15 | 550,641.03 | 1,394.66 | 4,290,505.01 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,734,091.03 | 18,936,746.72 | 8,080,775.86 | 53,479,583.61 |
| 减:所得税费用 | 7,533,431.14 | 5,965,795.37 | 4,369,303.15 | 4,932,433.43 |
| 六、净利润 | 13,200,659.89 | 12,970,951.35 | 3,711,472.71 | 48,547,150.18 |
| 持续经营净利润 | 13,200,659.89 | 12,970,951.35 | 3,711,472.71 | 48,547,150.18 |
| 归属于母公司股东的净利润 | 14,715,312.32 | 13,211,357.05 | 3,070,728.65 | 45,603,990.98 |
| 少数股东损益 | -1,514,652.43 | -240,405.7 | 640,744.06 | 2,943,159.2 |
| (一)基本每股收益 | 0.08 | 0.07 | 0.02 | 0.25 |
| (二)稀释每股收益 | 0.08 | 0.07 | 0.02 | 0.25 |
| 八、其他综合收益 | 1,097,419.76 | 1,097,419.76 | 986,432.02 | -4,122,565.46 |
| 归属于母公司股东的其他综合收益 | 1,097,419.76 | 1,097,419.76 | 892,030.48 | -3,728,035.95 |
| 九、综合收益总额 | 14,298,079.65 | 14,068,371.11 | 4,697,904.73 | 44,424,584.72 |
| 归属于母公司股东的综合收益总额 | 15,812,732.08 | 14,308,776.81 | 3,962,759.13 | 41,875,955.03 |
| 归属于少数股东的综合收益总额 | -1,514,652.43 | -240,405.7 | 735,145.6 | 2,548,629.69 |
| 公告日期 | 2024-10-29 | 2024-08-27 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |